APA (7th ed.) Citation

S, S., DA, Y., P, S., VK, G., M, P., P, P., . . . PA, F. (2026). Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer. Oncology and therapy, 14(1), 19. https://doi.org/10.1007/s40487-025-00394-8

Chicago Style (17th ed.) Citation

S, Sammons, Yardley DA, Sharma P, Gadi VK, Pegram M, Pathak P, Hu H, Sopher G, and Fasching PA. "Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer." Oncology and Therapy 14, no. 1 (2026): 19. https://doi.org/10.1007/s40487-025-00394-8.

MLA (9th ed.) Citation

S, Sammons, et al. "Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer." Oncology and Therapy, vol. 14, no. 1, 2026, p. 19, https://doi.org/10.1007/s40487-025-00394-8.